Format

Send to

Choose Destination
Int Arch Allergy Immunol. 2009;149(3):267-74. doi: 10.1159/000199723. Epub 2009 Feb 12.

Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults.

Author information

1
Center for Rheumatic Disease and Center for Allergy and Immunology, Kansas City, Mo. 64111, USA. niabdou@centerforrheumatic.com

Abstract

BACKGROUND:

The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy.

METHODS:

We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated.

RESULTS:

Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected.

CONCLUSIONS:

IgIV could be beneficial in patients with IgG subclass or antibody deficiency.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00417573.

PMID:
19218820
DOI:
10.1159/000199723
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center